Summary
• Profusa, Inc. (PFSA) shares rose 5% in pre-market trading, reaching $0.1600 after a trial update announcement.
• The company will present a clinical trial update on its Lumee™ Oxygen platform at the Paris Vascular Insights event on December 11-13, 2025.
• Profusa reported a reduced net debt of $14 million, but the stock has seen a 63.62% drop over the last quarter.
Profusa, Inc. (PFSA) is trading at $0.1600 in pre-market hours, marking a 5% increase from the last close of $0.1521. This movement comes after the company announced it will present a late-breaking update on its clinical trial at the Paris Vascular Insights event.
Clinical Trial Update Fuels Investor Interest
On November 24, 2025, Profusa disclosed that it has accepted an abstract to present a late-breaking clinical trial update focused on its Lumee™ Oxygen tissue monitoring platform. The presentation, titled “Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD),” will take place at the Paris Vascular Insights (PVI) 2025, scheduled for December 11-13 in Paris, France. This announcement has likely contributed to the uptick in investor interest.
The company emphasized advancements in its technology, which allows for continuous monitoring of an individual’s biochemistry—a significant step for patients suffering from peripheral artery disease.
Recent Earnings and Financial Highlights
Earlier in the month, on November 19, 2025, Profusa reported its third-quarter business and financial highlights, showcasing progress towards its 2026 revenue goals. Key achievements included a recapitalization that reduced net debt to $14 million as of October 31, indicating a healthier balance sheet for future growth. While today’s movement appears primarily driven by the upcoming clinical presentation, these recent financial updates are part of a broader context that investors are monitoring.
Market Performance Metrics
Profusa’s stock is experiencing significant volatility, exhibiting a 23.95% decrease over the past week and a stark 63.62% drop over the last quarter. The stock is currently 98% below its 52-week high and has an average trading volume of about 11.9 million over the last three months, compared to an average of 4.5 million in the past ten days. The relative strength index (RSI) stands at 31.13, suggesting the stock may be in oversold territory, which could attract bargain hunters.
Closing Thoughts
With shares reacting positively to the latest clinical trial news, market participants will keep a close watch on how Profusa navigates upcoming events and presentations. The recent announcements reflect efforts to bolster the company’s innovative profile in the digital health arena, and investors will likely monitor performance as further developments unfold in the next session.